Analysis Nectar Lifesciences Limited (NECLIFE)
5/30/2024
Analysis of Nectar Lifesciences Limited (NECLIFE)
Nectar Lifesciences Limited (NECLIFE) has shown a slight downward trend in the past few days. The Relative Strength Index (RSI) values have been hovering around 40-50, indicating a neutral to slightly bearish sentiment. The Moving Average Convergence Divergence (MACD) histogram has been negative, suggesting a bearish momentum.The stock price has been fluctuating around the moving averages, with the Simple Moving Average (SMA) and Exponential Moving Average (EMA) providing support and resistance levels. The Weighted Moving Average (WMA) has also been in line with the other moving averages.
Overall, the stock seems to be consolidating with a slightly bearish bias. Traders and investors may want to closely monitor the price action and key support levels for potential entry or exit points.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The results for the quarter ending on January 31, 2025, were released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and the most recent quarter reported is March 2024. The company shows good returns on assets and equity.
Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock price has fluctuated between a fifty-two-week low and high, with a positive change over the period.
Valuation metrics show a relatively high PEG ratio and forward PE ratio. The company's market capitalization and enterprise value are substantial, with a high price-to-book ratio and price-to-sales ratio. The enterprise value to EBITDA and revenue ratios are also notable.
The stock price summary includes beta, moving averages, and the range of prices over the past year.
Lastly, dividends and splits information shows the company's dividend dates, payout ratios, and historical dividend yields. The company has had a recent stock split and offers a forward annual dividend yield.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a need for cost management or pricing adjustments.
3. The gross profit margin has remained relatively stable over the years, suggesting efficient cost control measures.
4. Operating income has shown a positive trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
5. Net income has also been increasing consistently, reflecting the company's profitability and growth.
6. Earnings per share (EPS) have shown a slight fluctuation but have generally been on an upward trajectory.
7. The company has been able to manage its tax expenses effectively, as seen in the stable income tax figures.
8. Overall, the financial performance of the company in terms of revenue and profitability has been positive and improving over the years.
Balance Sheet
These are balance sheets. Here are the conclusions based on the provided data:1. The total assets have been increasing over the years, reaching the highest value in 2023 at $352,583,000,000.
2. Current assets fluctuate from year to year, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2023 at $209,017,000,000.
4. Total liabilities have also been increasing, reaching the highest value in 2023 at $290,437,000,000.
5. Shareholders' equity has been fluctuating, with the highest value in 2019 at $90,488,000,000.
6. The company has been relying more on non-current assets to support its operations over the years.
7. There is a significant amount of debt in the company's capital structure, both short-term and long-term.
8. The company has been investing in leases, machinery, furniture, and equipment to support its operations.
9. Retained earnings have been positive in most years, indicating profitability and reinvestment in the business.
10. The company has been managing its cash and cash equivalents strategically, with fluctuations in different years.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has been relatively stable over the years, indicating consistent operational performance.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show significant variability, with large amounts being spent on common stock repurchase and debt issuance/payments.
6. Investing activities also vary, with significant amounts being spent on the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company's financial activities show a mix of stability in operations and variability in financing and investing decisions.
Earnings estimate
Based on analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.33, with a low estimate of $1.27 and a high estimate of $1.36. This shows growth compared to the EPS of $1.26 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.53, with a low estimate of $1.44 and a high estimate of $1.63. This indicates an increase from the EPS of $1.46 from the same quarter last year.
3. For the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.59, with a low estimate of $6.43 and a high estimate of $6.92. This reflects growth compared to the EPS of $6.13 from the previous fiscal year.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average EPS estimate is $7.23, with a low estimate of $6.40 and a high estimate of $7.90. This suggests an increase from the EPS of $6.59 reported for the current fiscal year.
Overall, the analysts' estimates indicate a positive outlook for the company's earnings per share, with expected growth in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average growth rate for the past 5 years is 20.1% per annum.
6. Next 5 Years (per annum): The estimated growth rate for the next 5 years is 11% per annum.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the near term compared to the past performance. However, the company is still projected to maintain a double-digit growth rate over the next 5 years according to analyst consensus.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the low end at $164, the high end at $250, and the average forecast at $202.26. The current price of the security is $191.57, which is below the median and average forecast, indicating that some analysts may expect the price to increase in the future.
MACD of NECLIFE
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
